National Resilience, Inc., said that the Government of Canada will invest $163.8 million, through the Strategic Innovation Fund, in the company’s Ontario-based subsidiary Resilience Biotechnologies Inc. (RBI) to modernize and expand production capacity.   This project will help increase manufacturing capacity for vaccines and therapeutics, including novel technologies such as mRNA that are now being used to fight COVID-19. The expansion will build on RBI’s existing strengths as an important biom...